Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
$24.40
-3.7%
$22.70
$16.50
$26.55
$2.13BN/A59,959 shs16,331 shs
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$13.77
-0.6%
$14.08
$11.51
$21.50
$2.42B0.55100,582 shs87,577 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$39.06
+0.3%
$38.29
$31.42
$58.26
$2.50B1.31349,480 shs228,946 shs
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
$8.75
$644.67M0.01N/AN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
0.00%-7.85%-4.24%+30.69%+2,439,999,900.00%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
0.00%+2.76%-8.20%-13.45%-25.69%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.00%+0.33%-7.70%-1.64%-3.94%
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
1.9891 of 5 stars
3.02.00.00.02.20.01.9
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
1.9376 of 5 stars
3.51.00.00.02.82.50.0
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
3.00
BuyN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
2.00
Hold$19.0037.98% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
3.00
Buy$78.71101.52% Upside
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SVA, MLTX, HCM, and AAPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$61.00
5/13/2025
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/13/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$78.00 ➝ $80.00
5/13/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
4/30/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
3/27/2025
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
3/18/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$67.00
(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
$980.65M2.17N/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$630.20M3.81$0.56 per share24.51$4.27 per share3.22
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$8.15 per shareN/A
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
$448.27M1.44$0.17 per share38.95$120.83 per share0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/AN/A0.00N/AN/AN/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$100.78MN/A0.009.43N/AN/AN/AN/A6/18/2025 (Estimated)
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$36.01M-$2.30N/AN/AN/AN/A-15.54%-15.09%8/6/2025 (Estimated)
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
-$99.92MN/A0.00N/AN/AN/AN/AN/A

Latest SVA, MLTX, HCM, and AAPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.76-$0.63+$0.13-$0.63N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/A

Latest SVA, MLTX, HCM, and AAPG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2025
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
--$55.005/23/20255/23/20256/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
0.07
2.81
2.68
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/A
25.51
25.51
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
0.01
11.39
11.24
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
60087.11 millionN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
1,760174.32 million168.04 millionNot Optionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
264.01 million56.22 millionOptionable
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
3,26199.64 million86.89 millionOptionable

Recent News About These Companies

Sinovac Biotech
Sinovac Biotech to declare $55.00 per share special cash dividend
SINOVAC Announces Decision to Declare Cash Dividend

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$24.40 -0.95 (-3.75%)
As of 05/30/2025 02:44 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$13.77 -0.09 (-0.65%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$13.89 +0.12 (+0.87%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$39.06 +0.10 (+0.26%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$39.01 -0.05 (-0.13%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Sinovac Biotech stock logo

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.